Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor

Nat Rev Drug Discov. 2011 Aug 31;10(9):645-6. doi: 10.1038/nrd3546.
No abstract available

Publication types

  • News

MeSH terms

  • Animals
  • Carcinogens
  • Device Approval
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use*
  • Neoplasms / chemically induced
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors*
  • United States
  • United States Food and Drug Administration

Substances

  • Carcinogens
  • Hypoglycemic Agents
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors